Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octagam 10% replacement therapy in primary immunodeficiency diseases
ISRCTN63491981Phase 3Terminated
- Sponsor
- Octapharma
- Start
- Jan 2009
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label, single-arm trial of Human normal immunoglobulin G in Immunogenetic disorder, sponsored by Octapharma. Primary endpoints: Infusion-associated adverse event rate and Pharmacokinetic comparison. Started Jan 2009; status: terminated.
02
Drugs
Human normal immunoglobulin G
03
Conditions
Immunogenetic disorder
Beyond the preview
Go deeper on ISRCTN63491981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN63491981.